Best Peptides for Fat Loss (Ranked by Evidence)
Most peptide content ranks compounds by popularity or mechanism plausibility. This ranking uses a scoring framework weighted toward what actually matters for predicting real-world fat loss: human clinical trial data first, mechanism clarity second, effect size third, safety profile fourth.
Human trial data
Randomised controlled trials in humans — the gold standard
Mechanism clarity
How well understood is the fat-loss pathway?
Effect size
Magnitude of measurable weight/fat loss in studies
Safety profile
Documented side effects and long-term tolerance
Proven Human Data
Semaglutide (2.4mg)
Human data
5/5
Mechanism
5/5
Effect size
5/5
Safety
4/5
The current benchmark for pharmacological weight loss. SCALE trial: ~15% mean body weight loss. SELECT trial: 20% reduction in cardiovascular events. GLP-1 receptor agonist with the longest clinical track record for obesity.
Tirzepatide (15mg)
Human data
5/5
Mechanism
5/5
Effect size
5/5
Safety
4/5
SURMOUNT-1: 22.5% mean body weight loss — the largest effect size of any weight loss compound in clinical trials. Dual GLP-1 + GIP mechanism. SURMOUNT-5 direct comparison confirmed superiority over semaglutide.
GH-Mediated Lipolysis
CJC-1295 + Ipamorelin Stack
Human data
2/5
Mechanism
4/5
Effect size
3/5
Safety
4/5
GH-mediated lipolysis is real and well-understood. CJC-1295 (GHRH analogue) + Ipamorelin (GHRP) produce synergistic GH pulses that drive fat mobilisation — particularly visceral fat. Limited direct human RCT data for fat loss, but GH's lipolytic effects are documented in GH-deficient populations.
Fat-Targeted GH Fragments
AOD-9604
Human data
2/5
Mechanism
3/5
Effect size
2/5
Safety
3/5
GH fragment 176-191 — theoretically targets fat cells directly via lipolytic pathway without the IGF-1 and insulin effects of full GH. Phase 2 trial data showed modest fat loss. Mechanism is plausible; effect size in humans is unimpressive relative to GLP-1 agents.
Tesamorelin
Human data
4/5
Mechanism
4/5
Effect size
3/5
Safety
4/5
FDA-approved for HIV-associated lipodystrophy — the only GH-axis peptide with approved human fat reduction data. Specifically reduces visceral (abdominal) fat via GHRH receptor activation. Fat-targeted mechanism is well-validated; applicability to general obesity is more limited.
If fat loss is the primary goal and human evidence matters, GLP-1 agonists (semaglutide, tirzepatide) operate in a completely different category from every other compound listed. Their effect sizes in human RCTs — 15–22% body weight loss — are simply not achieved by any other peptide with current human data.
GH secretagogues (CJC-1295, Ipamorelin, Tesamorelin) are real, mechanism-supported tools for improving body composition — primarily through lipolysis and lean mass preservation — but their documented fat loss in human trials is modest compared to GLP-1 agents.
AOD-9604 and peptides with primarily preclinical support are speculative for fat loss purposes at this stage of research.
Research use only. Rankings are based on available published evidence. Research-grade compounds are not pharmaceutical substitutes. Not medical advice.
Weight Loss Peptides Guides
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →